Apoptosis pathway-targeted drugs - from the bench to the clinic

被引:69
作者
Cummings, J [1 ]
Ward, TH [1 ]
Ranson, M [1 ]
Dive, C [1 ]
机构
[1] Paterson Inst Canc Res, Canc Res UK, Clin & Expt Pharmacol Grp, Manchester M20 4BX, Lancs, England
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2004年 / 1705卷 / 01期
关键词
apoptosis-targeted therapy; early clinical trial; quality assurance; assay validation; biomarker; pharmacodynamic assay;
D O I
10.1016/j.bbcan.2004.09.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It is an exciting time for cancer researchers in the field of apoptotic cell death. The avalanche of discoveries over the past decade or so regarding how apoptosis is regulated begins to be exploited for therapeutic benefit as the first apoptosis-targeted drugs enter early clinical trials. This chapter provides a selective review on the development of such drugs. We also outline issues regarding the regulation and design of early clinical trials of this type of molecularly targeted agent. Finally, we discuss the biomarkers and surrogate pharmacodynamic endpoint assays currently available to chart the efficacy of apoptosis-inducing anticancer therapy. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:53 / 66
页数:14
相关论文
共 146 条
  • [1] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
    Albanell, J
    Rojo, F
    Averbuch, S
    Feyereislova, A
    Mascaro, JM
    Herbst, R
    LoRusso, P
    Rischin, D
    Sauleda, S
    Gee, J
    Nicholson, RI
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 110 - 124
  • [2] Survivin, versatile modulation of cell division and apoptosis in cancer
    Altieri, DC
    [J]. ONCOGENE, 2003, 22 (53) : 8581 - 8589
  • [3] A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
    Ambrosini, G
    Adida, C
    Altieri, DC
    [J]. NATURE MEDICINE, 1997, 3 (08) : 917 - 921
  • [4] ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
    Anderson, NG
    Ahmad, T
    Chan, K
    Dobson, R
    Bundred, NJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) : 774 - 782
  • [5] The Bcl-2 protein family
    Antonsson, B
    Martinou, JC
    [J]. EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) : 50 - 57
  • [6] Arlt A, 2002, INT J CLIN PHARM TH, V40, P336
  • [7] AWYERS CL, 2002, CURR OIPIN INVESTIG, V3, P478
  • [8] Badran A, 2003, ANTICANCER RES, V23, P589
  • [9] Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
  • [10] Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-β and -γ
    Benimetskaya, L
    Wittenberger, T
    Stein, CA
    Hofmann, HP
    Weller, C
    Lai, JC
    Miller, P
    Gekeler, V
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3678 - 3688